Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Fri, 11 Sep 2026 07:00:00 -0400

Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst

Access the video webcast here

ISELIN, N.J., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that its pre-recorded fireside chat from the H.C. Wainwright 28th Annual Global Investment Conference (the “Conference”) is now available for on-demand viewing here.

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Fri, 11 Sep 2026 07:00:00 -0400

Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst

Access the video webcast here

Outlook Therapeutics CEO discusses Lytenava FDA approval and U.S. launch

Thu, 10 Sep 2026 09:10:17 -0400

Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced that Chief Executive Officer Bob Jahr participated in a Virtual Investor CEO Connect segment to discuss the FDA approval of LYTENAVA (bevacizumab-vikg) and the company's plans for a U.S. commercial launch before the end of 2026.

LYTENAVA is described by the company as the only FDA-approved ophthalmic formulation of bevacizumab, indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD). The drug has also received Marketing Authorization from the European Commission and the UK's Medicines and Healthcare products Regulatory Agency for the same indication.

During the segment, Jahr discussed the company's goal of achieving more

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Thu, 10 Sep 2026 09:10:00 -0400

Access the segment here

ISELIN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in a Virtual Investor CEO Connect segment discussing the significance of the FDA approval of LYTENAVA and the Company’s plans for its U.S. commercial launch.

During the segment, Mr. Jahr discusses the potential of LYTENAVA to address the

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Thu, 10 Sep 2026 09:10:00 -0400

Access the segment here

During the segment, Mr. Jahr discusses the potential of LYTENAVA to address the

Form 8-K Outlook Therapeutics, For: Aug 23

Thu, 27 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260827/26990014.html

Form 8-K Outlook Therapeutics, For: Aug 23

Thu, 27 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260827/26990014.html

Outlook Therapeutics names Kevin Lundquist as CFO ahead of U.S. launch

Thu, 27 Aug 2026 16:05:34 -0400

Outlook Therapeutics, Inc. (Nasdaq: OTLK) has appointed Kevin Lundquist as Chief Financial Officer, effective September 1, 2026, as the biopharmaceutical company prepares for the U.S. commercial launch of its FDA-approved drug LYTENAVA (bevacizumab-vikg).

Lundquist brings more than 20 years of corporate finance and capital markets experience across the pharmaceutical, biotechnology, medical technology, and manufacturing industries. He most recently served as CFO of CapsoVision, Inc., a commercial-stage medical technology company, where he led the company through its 2025 IPO process and oversaw finance, operations, SEC reporting, and capital raises.

Prior to CapsoVision, Lundquist was CFO of Abzena Biologics, a private equity-backed contract development

Outlook Therapeutics names Kevin Lundquist as CFO ahead of U.S. launch

Thu, 27 Aug 2026 16:05:34 -0400

Prior to CapsoVision, Lundquist was CFO of Abzena Biologics, a private equity-backed contract development

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Thu, 27 Aug 2026 16:05:00 -0400

Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industries

Deep expertise spans commercial operations, capital markets, public company finance, and building scalable financial and operational infrastructure

Appointment strengthens financial and operational infrastructure as Company prepares for U.S. commercial launch following FDA approval of LYTENAVA™

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Thu, 27 Aug 2026 16:05:00 -0400

Appointment strengthens financial and operational infrastructure as Company prepares for U.S. commercial launch following FDA approval of LYTENAVA™

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

Thu, 27 Aug 2026 09:01:00 -0400

Video webcast now available here

ISELIN, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in the Virtual Investor “Why Now” on-demand conference.

During the segment, Mr. Jahr highlighted why he believes Outlook Therapeutics is entering a transformative period following the FDA’s approval of LYTENAVA™ on July 24, 2026, making it the

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

Thu, 27 Aug 2026 09:01:00 -0400

Video webcast now available here

During the segment, Mr. Jahr highlighted why he believes Outlook Therapeutics is entering a transformative period following the FDA’s approval of LYTENAVA™ on July 24, 2026, making it the

Form SCHEDULE 13G Outlook Therapeutics, Filed by: CVI Investments, Inc.

Wed, 19 Aug 2026 13:47:00 -0400

si-local-file:///var/storage/secattach/20260819/26949380.html

Form SCHEDULE 13G Outlook Therapeutics, Filed by: CVI Investments, Inc.

Wed, 19 Aug 2026 13:47:00 -0400

si-local-file:///var/storage/secattach/20260819/26949380.html

Form 10-Q Outlook Therapeutics, For: Jun 30

Tue, 18 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260818/26945587.html

Form 10-Q Outlook Therapeutics, For: Jun 30

Tue, 18 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260818/26945587.html

Outlook Therapeutics Inc. (OTLK) PT Lowered to $4 at Brookline Capital Markets

Tue, 18 Aug 2026 15:49:00 -0400

Brookline Capital Markets analyst Kemp Dolliver lowered the price target on Outlook Therapeutics Inc. (NASDAQ: OTLK) to $4.00 (from $6.00) while maintaining a Buy rating.

The analyst comments "Conclusion – FDA approval of LYTENAVA (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration (nAMD), or wet AMD, came several days ahead of the July 29 PDUFA date. The label has no restrictions, as expected. Management plans to launch LYTENAVA in Q1:C2027. The $55MM stock and warrants offering extends the runway into Q2:C2027 (June). Management sees US revenue of $500MM or more in the US in 2030, ahead of our prior $395MME.

Outlook Therapeutics Inc. (OTLK) PT Lowered to $4 at Brookline Capital Markets

Tue, 18 Aug 2026 15:49:00 -0400

Brookline Capital Markets analyst Kemp Dolliver lowered the price target on Outlook Therapeutics Inc. (NASDAQ: OTLK) to $4.00 (from $6.00) while maintaining a Buy rating.

Form NT 10-Q Outlook Therapeutics, For: Jun 30

Mon, 17 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260817/26937951.html

Form NT 10-Q Outlook Therapeutics, For: Jun 30

Mon, 17 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260817/26937951.html

Form 4 Outlook Therapeutics, For: Aug 14 Filed by: Jahr Robert Charles

Fri, 14 Aug 2026 20:58:00 -0400

si-local-file:///var/storage/secattach/20260814/26933290.html

Form 4 Outlook Therapeutics, For: Aug 14 Filed by: Jahr Robert Charles

Fri, 14 Aug 2026 20:58:00 -0400

si-local-file:///var/storage/secattach/20260814/26933290.html

Form SCHEDULE 13D/A Outlook Therapeutics, Filed by: GMS Ventures & Investments

Fri, 14 Aug 2026 19:54:00 -0400

si-local-file:///var/storage/secattach/20260814/26933248.html

Form SCHEDULE 13D/A Outlook Therapeutics, Filed by: GMS Ventures & Investments

Fri, 14 Aug 2026 19:54:00 -0400

si-local-file:///var/storage/secattach/20260814/26933248.html

StreetInsider.com News Articles

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Outlook Therapeutics CEO discusses Lytenava FDA approval and U.S. launch

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Form 8-K Outlook Therapeutics, For: Aug 23

Form 8-K Outlook Therapeutics, For: Aug 23

Outlook Therapeutics names Kevin Lundquist as CFO ahead of U.S. launch

Outlook Therapeutics names Kevin Lundquist as CFO ahead of U.S. launch

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

Form SCHEDULE 13G Outlook Therapeutics, Filed by: CVI Investments, Inc.

Form SCHEDULE 13G Outlook Therapeutics, Filed by: CVI Investments, Inc.

Form 10-Q Outlook Therapeutics, For: Jun 30

Form 10-Q Outlook Therapeutics, For: Jun 30

Outlook Therapeutics Inc. (OTLK) PT Lowered to $4 at Brookline Capital Markets

Outlook Therapeutics Inc. (OTLK) PT Lowered to $4 at Brookline Capital Markets

Form NT 10-Q Outlook Therapeutics, For: Jun 30

Form NT 10-Q Outlook Therapeutics, For: Jun 30

Form 4 Outlook Therapeutics, For: Aug 14 Filed by: Jahr Robert Charles

Form 4 Outlook Therapeutics, For: Aug 14 Filed by: Jahr Robert Charles

Form SCHEDULE 13D/A Outlook Therapeutics, Filed by: GMS Ventures & Investments

Form SCHEDULE 13D/A Outlook Therapeutics, Filed by: GMS Ventures & Investments